

Medibio reports strong response from US Corporates and Universities US broker initiates research coverage

Sydney, Australia – 17 August 2015: Medibio Limited (**MEB** or the **Company**) is pleased to announce an update on its recent US visit. The purpose of the trip was primarily to undertake a series of meetings with major corporates, which had expressed an interest in partnering with Medibio, and to discuss research collaboration with a number of leading US Universities. The company also took the opportunity to gauge potential US investor interest in the company.

US Corporates

Medibio has executed Non-Disclosure Agreements (NDA's) with four significant US based corporates and is likely to execute additional NDA's in the coming weeks. These corporates cover a spectrum of device manufacturers, integrated health and wellness providers, and technology companies. Whilst negotiations are at an early stage Medibio is excited by these early discussions confident that it will be able to crystalise at least one of these opportunities in the near term.

US Universities

The company had a series of positive meetings with a number of the leading Universities in the US and Canada. All the Institutions visited have expressed their desire to collaborate with Medibio on research. Importantly this research will focus on not just depression but other mental health disorders including Post Traumatic Stress Disorder, Anxiety Disorder, mixed depression and anxiety, and Panic Disorder. Additionally some of these institutions have data sets including 12 hour ECG data and corresponding clinical psychiatric diagnoses which can be used fast track blinded validation trials of Medibio's technology. Medibio anticipates it will be in a position to begin to execute formal collaboration agreements and announce additional details of these studies in the coming month.

US Investor Interest

The company received an extremely favorable response at both the investor and broker level. Medibio is pleased to advise that one US brokerage house has commenced coverage of Medibio with an initial research report released. A copy of this report is available on Medibio's website. A second US brokerage firm is also completing a research report prior to initiating coverage of Medibio and the company has received strong interest from a number of other US brokers.

Further Information:		Website: www.medibio.com.au	
Medibio Shareholder Enquiries to: Kris Knauer CEO and Director Medibio Limited kris.knauer@medibio.com.au T: +61 (0)411 885979		Medibio Media Enquiries to: Peter Taylor NWR Communications Peter@nwrcommunications.com.au T: +61 (0)412 036 231	